Why is Nectar Lifesci. falling/rising?

As of 28-Jul, Nectar Lifescience Ltd's stock price is currently at 16.70, reflecting a decline of 0.38, or 2.22%. The stock has been underperforming significantly, having fallen for the last five consecutive days, resulting in a total return of -8.99% over that period. Additionally, it has shown a stark decline of 24.74% over the past month and a staggering 57.18% year-to-date. The company is trading below all key moving averages, indicating a bearish trend. Financially, Nectar Lifescience is facing severe challenges, including operating losses and a high debt-to-EBITDA ratio of 7.73 times, which diminishes its ability to service debt. The company's profitability is also weak, with a return on equity of only 0.55% and a negative EBITDA, leading to a significant drop in profit after tax compared to previous quarters. In the broader market context, the stock's performance has been notably worse than the benchmark, with the Sensex only declining by 1.59% over the past week and showing a modest increase of 3.52% year-to-date. This consistent underperformance against the benchmark highlights the company's struggles, particularly as it has generated negative returns over the last three years compared to the overall market. The high percentage of pledged promoter shares, at 99.6%, further exacerbates the stock's downward pressure in a declining market, contributing to investor hesitance and reduced participation in trading. Overall, these factors collectively explain the stock's recent decline.